KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).

Jin Seok Kim, Yang Song, Wei-Ying Jen, C S Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Jae Hoon Lee, Kihyun Kim, Shigeki Ito, Jeffrey Shang-Yi Huang, Chang Ki Min, Melissa Ooi Gaik Ming, Sanjay de Mel, Cinnie Soekojo, Xinhua Li, Neha Awasthi, Yogesh Pokharkar, Brian Gm Durie, Wee-Joo Chng

Blood Cancer J 15(1) 155

PMID41052983
PMCIDPMC12501207
DOI10.1038/s41408-025-01356-z
发表日期2025-10-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Pomalidomide has been shown to improve survival in patients with relapsed/refractory myeloma (RRMM). However, the optimal pomalidomide-based combinations in RRMM are not known. This study compared pomalidomide, cyclophosphamide, dexamethasone (PCD) with pomalidomide and dexamethasone (PD) in Asian patients with RRMM. Patients were randomly assigned to receive PCD or PD. Patients received pomalidomide at 4 mg from days 1 to 21, dexamethasone at 40 mg once a week, and those in the PCD arm received cyclophosphamide at 400 mg once weekly for three weeks. The primary endpoint was progression-free survival. One hundred and twenty-two patients were randomized (62 PCD, 60 PD). Baseline characteristics were comparable between both arms. The median prior lines of therapy were three. At a median follow-up of 13.5 (median range 9-18) months, median progression free survival was significantly longer at 10.9 months (95% confidence interval 7.1-27.7) in the PCD group compared with 5.8 months (95% CI, 4.4-6.9) in the PD group (hazard ratio 0.43; p < 0.001). Adverse events rates were similar in both arms. The most common grade ≥3 adverse events were hematological toxicities and pneumonia. 34 deaths occurred during the study (PCD: 17; PD: 17) and three were deemed to be related to study treatment. In Asian patients with RRMM after exposure to proteasome inhibitor and lenalidomide, progression-free survival was significantly prolonged with the addition of cyclophosphamide to PD, with a manageable safety profile.Trial ID: Registered at www.clinicaltrials.gov : NCT03143049.

KM 提取结果

3 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 3

Fig. 3 Kaplan-Meier curves of the mITT population for progression-free survival (PFS).

progression-free_survival_PFS_

progression-free survival

Fig. 3 · Panel progression-free_survival_PFS_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel progression-free_survival_PFS_ 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal
查看结果
KM Figure1 个面板

Fig. 4

Fig. 4 Kaplan-Meier curves of the mITT population for duration of response (DOR).

DOR

Duration of Response

Fig. 4 · Panel DOR

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel DOR 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
KM Figure1 个面板

Fig. 6

Fig. 6 Kaplan-Meier curves of the mITT population for Overall Survival (OS).

Overall_Survival

OS

Fig. 6 · Panel Overall_Survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_Survival 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Study design.
非 KM Figure
Fig. 2Fig. 2 Consort Diagram.
非 KM Figure
Fig. 5Fig. 5 Overall Response Rate (ORR). Unadjusted ORR was used in this graph.
非 KM Figure
Fig. 7Fig. 7 Forest plot of treatment comparison for PFS by subgroup (mITT population).
非 KM Figure